Introduction
============

Intrahepatic cholangiocarcinoma (ICC) is the second most frequent liver malignancy and originates from intrahepatic bile duct epithelial cells ([@ref-4]). ICC accounts for approximately 10%--15% of primary liver cancers and is characterized by its poor prognosis, with a 5-year survival rate of 25--35% after surgical resection ([@ref-7]; [@ref-30]). The main factor in the poor prognosis of ICC is the presence of distant metastasis at the time of diagnosis, which heavily affects the implementation and curative effect of therapy ([@ref-31]). For example, the 5-year OS rates for stage III and stage IV disease are 10% and 0%, respectively ([@ref-28]). Thus, special attention should be paid to novel available biomarkers for both differential diagnoses and prognostic predictions of ICC.

Ubiquitin-conjugating enzyme E2T (UBE2T, also called HSPC150), a member of the E2 family, participates with particular E3 ubiquitin ligase in degrading target substrates ([@ref-11]). UBE2T was initially found in a case of Fanconi anemia ([@ref-18]). It also plays a crucial role in cellular development ([@ref-16]). Importantly, the UBE2T gene, located at 1q32.1, has been reported to be overexpressed in several malignant tumors, such as bladder cancer, hepatocellular carcinoma, myeloma, and renal cell carcinoma ([@ref-8]; [@ref-9]; [@ref-17]; [@ref-36]). However, little is known about the correlation between UBE2T and ICC.

To better characterize the effects of UBE2T, we examined its expression in ICC, the intrahepatic bile duct (IHBD), and biliary intraepithelial neoplasia (BilIN). Then, we assessed its utility in the differential diagnosis of benign and malignant bile duct diseases. Finally, the prognostic impact of UBE2T on ICC patients was examined.

Materials & Methods
===================

Patients
--------

Thirteen IHBD, 23 BilIN-1/2, and 11 BilIN-3 tissues from April 2008 to November 2013 were obtained, and 401 ICC formalin-fixed paraffin-embedded (FFPE) specimens diagnosed at the Eastern Hepatobiliary Surgery Hospital, Shanghai, from July 2000 to December 2008 were included; all specimens were classified into the diagnostic or prognostic group. Two experienced pathologists reexamined the associated hematoxylin and eosin (HE)-stained slides containing FFPE tissues. The inclusion criteria were as follows: (1) pathological diagnosis according to the histological diagnostic criteria of the WHO; (2) no preoperative anti-cancer treatment; (3) partial hepatectomy with curative intent; and (4) the existence of complete data for both the UBE2T H-score and follow-up period. Laboratory tests were conducted on blood samples obtained before surgery. The tumor diameter and surgical margin were tested on the largest tumor by using gross pathologic specimens. Written informed consent was obtained from all patients. The study protocol was approved by the Research Ethics Committee of Eastern Hepatobiliary Surgery Hospital (EHBHKY2015-01-001).

Follow-up
---------

The endpoints of this study were time to recurrence (TTR) and overall survival (OS). TTR was defined from the date of hepatic resection until the detection of tumor recurrence, death or last observation. OS was defined as the interval between surgery and death or last observation. The patients' follow-up examinations were performed every 3 months during the first year after surgery and every 6 months thereafter. At each visit, the tests for liver functions, alpha fetoprotein (AFP), carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA199) and an abdominal ultrasound were conducted. Contrast-enhanced computed tomography (CT) scanning or magnetic resonance imaging (MRI) was performed once every 3-6 months or when recurrence or metastasis was suspected. Follow-up data were collected until September 2014.

Data mining of the TCGA database
--------------------------------

Data on the mRNA expression of UBE2T and associated clinical prognosis were obtained from the data library of The Cancer Genome Atlas (TCGA).

Construction of tissue microarrays and IHC
------------------------------------------

As previously reported, tissue microarray construction, IHC, and H-score measurements were performed for all the cases ([@ref-10]; [@ref-33]). The HE-stained slides of all patients were reviewed and identified, and then, the typical areas were premarked in the paraffin blocks. The marked areas of each block were punched by tissue cylinders with diameters of 1.5 mm. As in previous studies, the representativeness of a 0.6-mm core in the tissue microarray was equal to that of a larger slide for the optimization of standardized experimental conditions and for assessing focal and heterogeneous expression types ([@ref-1]; [@ref-12]), so the expression characteristics of a tissue specimen of this size were considered to be representative of the whole tissue slice. Then, the obtained tissues were incorporated into a recipient paraffin block afterwards. After the sections were sliced to 4-µm thickness, they were placed on slides coated with 3-aminopropyltriethoxysilane.

Paraffin sections were deparaffinized in xylene and rehydrated through decreasing concentrations of ethanol (100%, 95%, and 85% for 5 min each). Antigens were unmasked by microwave irradiation for 3 min in pH 6.0 citric buffer and cooled at room temperature for 60 min. Endogenous peroxidase activity was blocked by incubation in 3% H~2~O~2~/phosphate-buffered saline, and goat serum was used to block nonspecific binding sites. The primary antibody was as follows: rabbit polyclonal antibody to UBE2T (GTX106464; GeneTax, USA; 1:200 dilution). An EnVision Detection kit (GK500705; Gene Tech, Shanghai, China) was employed to visualize UBE2T. Tissue sections were counterstained with hematoxylin for 5 min. Negative control slides without primary antibody were generated for all assays.

The UBE2T-stained slides were scanned on a KFBIO KF-PRO-005-EX digital section scanner (Konfoong Biotech International Co., Ltd., Yuyao, China). Images were analyzed using the HALO 2.0 CytoNuclear Quantification algorithm (Indica Labs), a whole-slide imaging data analysis software program that measures and reports individual cell data that is represented as the percentage of positive cells per mm^2^ tissue. The H-score was used to express the measurement of the HALO software ([Fig. S1](#supp-1){ref-type="supplementary-material"}) ([@ref-13]). $$\documentclass[12pt]{minimal}
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X-tile analysis
---------------

The optimal cutoff point used for the survival analysis of the different UBE2T expression groups was calculated with X-tile software version 3.6.1 (Yale University School of Medicine, New Haven, CT, USA) ([@ref-5]). UBE2T expression was represented as the H-score, and X-tile plots were used for optimization of cutoff points based on follow-up data. Statistical significance was evaluated by a standard log-rank method using the cutoff score derived from 401 ICC cases, with the *P* value obtained from a lookup table.

Statistical analysis
--------------------

Continuous variables were compared using the Mann--Whitney test or Student's *t*-test. The chi-squared test or Fisher's exact test were used to analyze categorical variables when appropriate. Multiple sets of measurement data were compared by means of a multiple independent samples nonparametric test (Kruskal-Wallis test). Receiver operating characteristic (ROC) area under the curve (AUC) analysis showed the discriminatory power of the putative markers. The TTR and OS rates were calculated by the Kaplan--Meier method and log-rank test. Univariate and multivariate prognostic analyses were conducted using the Cox proportional hazards regression model. A *P* value less than 0.05 indicated statistical significance. All statistical analyses were performed using SPSS 24.0 software (SPSS, Chicago, IL, USA) and GraphPad Prism 8.0.1 (GraphPad Software, La Jolla, CA, USA).

Results
=======

Expression differences in and prognostic impact of UBE2T on ICC based on the TCGA database
------------------------------------------------------------------------------------------

Based on the data obtained from the TCGA database, 9 cases of normal tissue and 36 cases of ICC were analyzed. The UBE2T mRNA expression level in the ICC tissues was obviously higher than that in the normal tissues (*P* \< 0.0001, [Fig. 1A](#fig-1){ref-type="fig"}). For the 28 ICC patients with follow-up data, when the median UBE2T expression value was used as the cutoff point, the survival analysis showed no difference in OS (*P* = 0.3679, [Fig. 1B](#fig-1){ref-type="fig"}).

![UBE2T levels in normal tissue and ICC (A) and its prognostic impact on ICC (B) based on the TCGA database.](peerj-08-8454-g001){#fig-1}

UBE2T expression profiles of the IHBD, BilIN-1/2, BilIN-3, and ICC and its diagnostic value
-------------------------------------------------------------------------------------------

The H-scores for 13, 23, 11, and 401 IHBD, BilIN-1/2, BilIN-3, and ICC tissues, respectively, were calculated for UBE2T expression-level comparisons. The immunohistochemical expression characteristics of UBE2T in the IHBD, BilIN-1/2, BilIN-3, and ICC tissues are shown in [Fig. 2](#fig-2){ref-type="fig"}. The UBE2T expression level of the ICCs was significantly higher than that of the IHBD (*P* = 0.003), BilIN-1/2 (*P* \< 0.001), and BilIN-3 tissues (*P* = 0.012) ([Fig. 3A](#fig-3){ref-type="fig"}). Additionally, the ROC curve revealed that there was a strong discrimination between ICC and the IHBD (AUC = 0.782), BilIN-1/2 (AUC =0.774), and BilIN-3 tissues (AUC = 0.776) ([Fig. 3](#fig-3){ref-type="fig"}). The baseline characteristics of the three latter groups are shown in [Table S1](#supp-1){ref-type="supplementary-material"}.

![Immunohistochemical expression characteristics of UBE2T in the IHBD (A), BilIN-1/2 (B), BilIN-3 (C), and ICC (D) (20×).](peerj-08-8454-g002){#fig-2}

![UBE2T expression in the IHBD, BilIN-1/2, BilIN-3, and ICC by immunohistochemistry (A).\
ROC curve analysis of UBE2T for differential diagnosis (B: IHBD and ICC, (C): BilIN-1/2 and ICC, (D): BilIN-3 and ICC).](peerj-08-8454-g003){#fig-3}

Clinicopathological characteristics of the ICC cohort
-----------------------------------------------------

For the 401 patients with ICC, analysis by X-tile software was performed to assess the best cutoff point for the H-score of UBE2T. Using a standard log-rank method, with P values acquired from a lookup table for TTR and OS, we selected an H-score of \<28.96 as the best cutoff point. A total of 288 and 113 patients were divided into low- and high-expression groups, respectively ([Fig. S2](#supp-1){ref-type="supplementary-material"}). The baseline characteristics of the ICC patients are shown in [Table 1](#table-1){ref-type="table"}. The median follow-up time was 42.1 months.
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###### Baseline characteristics of ICC patients with different expression of UBE2T (*N* = 401).

![](peerj-08-8454-g005)

  Characteristics   Low (*N* = 288)   High (*N* = 113)   *P* value
  ----------------- ----------------- ------------------ -----------
  Age, years        53.58 ± 11.14     52.82 ± 9.83       0.688
  Sex                                                    0.618
  Male              211(73.3%)        80(70.8%)          
  Female            77(26.7%)         33(29.2%)          
  AFP, ng/mL        81.69 ± 236.65    112.83 ± 286.36    0.069
  CEA, ng/mL        14.17 ± 84.30     14.76 ± 94.78      0.920
  CA199, ng/mL      169.47 ± 274.57   140.65 ± 221.52    0.692
  TBIL, µmol/L      15.58 ± 15.57     24.66 ± 55.93      0.009
  ALB, g/L          42.15 ± 4.27      41.23 ± 4.67       0.144
  ALT, U/L          47.55 ± 67.75     43.06 ± 44.44      0.665
  GGT, U/L          108.22 ± 129.31   155.61 ± 256.95    0.060
  ALP, U/L          122.85 ± 96.98    130.06 ± 105.59    0.377
  HBsAg                                                  0.085
  Positive          165(57.3%)        54(47.8%)          
  Negative          123(42.7%)        59(52.2%)          
  Tumor size, cm    6.15 ± 3.35       7.33 ± 3.56        0.002
  Tumor number                                           0.070
  Single            235(81.6%)        83(73.5%)          
  Multiple          53(18.4%)         30(26.5%)          
  Surgical margin                                        0.776
  \<1 cm            213(74.0%)        82(72.6%)          
  ≥1 cm             75(26.0%)         31(27.4%)          
  Liver cirrhosis                                        0.795
  Yes               75(26.0%)         28(24.8%)          
  No                213(74.0%)        85(75.2%)          
  MVI                                                    0.018
  Positive          53(18.4%)         33(29.2%)          
  Negative          235(81.6%)        80(70.8%)          
  TNM                                                    0.924
  I--II             241(83.7%)        95(84.1%)          
  III--IV           47(16.3%)         18(15.9%)          

**Notes.**

ICCintrahepatic cholangiocarcinomaAFPalpha fetoproteinCEAcarcinoembryonic antigenCA199carbohydrate antigen 19-9TBILtotal bilirubinALBalbuminALTalanine aminotransferaseGGTgamma glutamyltransferaseALPalkaline phosphataseHBsAghepatitis B surface antigenMVImicrovascular invasion, TNM tumor-node-metastasis

Impact of UBE2T on the clinical outcomes
----------------------------------------

Kaplan--Meier analysis was conducted to compare the prognoses of ICC patients with low or high expression of UBE2T. The results suggested that the high-expression group had a shorter TTR and OS than the low-expression group. The median TTRs of the high- and low-expression groups were 5.7 months and 8.5 months, respectively. The 1-, 3-, and 5-year TTR rates were 69.3%, 85.6%, and 100%, respectively, in the high-expression group and 56.2%, 72.5%, and 86.2%, respectively, in the low-expression group (*P* = 0.005, [Fig. 4A](#fig-4){ref-type="fig"}). The median OS times of the high- and low-expression groups were 18.4 months and 24.2 months, respectively. The corresponding 1-, 3-, and 5-year OS rates were 64.4%, 25.7%, and 1.9%, respectively, in the high-expression group and 73.4%, 40.7%, and 22.2%, respectively, in the low-expression group (*P* \< 0.001, [Fig. 4B](#fig-4){ref-type="fig"}).

![Cumulative incidences in the time to recurrence (A) and overall survival (B) curves comparisons for high and low expression of UBE2T.](peerj-08-8454-g004){#fig-4}

Independent prognostic factors of TTR and OS
--------------------------------------------

Univariable analysis by means of Cox proportional hazards regression revealed that AFP, CA199, tumor size, tumor number, liver cirrhosis, microvascular invasion (MVI), tumor-node-metastasis (TNM) staging, and UBE2T were associated with TTR (all *P* \< 0.05, [Table 2](#table-2){ref-type="table"}) and that AFP, CA199, albumin (ALB), alkaline phosphatase (ALP), tumor size, tumor number, MVI, TNM staging, and UBE2T were related to OS (all *P* \< 0.05, [Table 3](#table-3){ref-type="table"}). Multivariable analysis indicated that multiple tumor nodules, poorer TNM staging, and high UBE2T expression were independent risk factors for TTR (all *P* \< 0.05, [Table 2](#table-2){ref-type="table"}) and that higher CA199, lower ALB, larger tumor size, multiple tumor nodules, presence of MVI, poorer TNM staging, and high UBE2T expression were significant risk factors for OS (all *P* \< 0.05, [Table 3](#table-3){ref-type="table"}).
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###### Independent risk factors of time to recurrence.

![](peerj-08-8454-g006)

  Characteristics                          Univariate           Multivariate                        
  ---------------------------------------- -------------------- -------------- -------------------- ---------
  Age, year                                0.990(0.980,1.001)   0.067                               
  Sex: female vs. male                     0.858(0.664,1.108)   0.240                               
  AFP, ng/mL                               1.000(1.000,1.001)   0.040                               
  CEA, ng/mL                               1.000(0.999,1.001)   0.922                               
  CA199, ng/mL                             1.000(1.000,1.001)   0.024                               
  TBIL, µmol/L                             0.999(0.995,1.003)   0.484                               
  ALB, g/L                                 0.996(0.970,1.022)   0.737                               
  ALT, U/L                                 1.001(0.999,1.002)   0.442                               
  GGT, U/L                                 1.000(1.000,1.001)   0.251                               
  ALP, U/L                                 1.001(1.000,1.002)   0.068                               
  HBsAg: positive vs. negative             0.831(0.663,1.043)   0.110                               
  Tumor size, cm                           1.074(1.044,1.105)   \<0.001                             
  Tumor number: multiple vs. single        1.943(1.483,2.545)   \<0.001        1.867(1.423,2.449)   \<0.001
  Surgical margin: \<1 cm vs. ≥1 cm        1.299(0.999,1.689)   0.051                               
  Liver cirrhosis: positive vs. negative   0.690(0.525,0.906)   0.008                               
  MVI: positive vs. negative               1.363(1.035,1.794)   0.027                               
  TNM: III--IV vs. I--II                   1.460(1.075,1.981)   0.015          1.447(1.066,1.964)   0.018
  UBE2T: high vs. low                      1.422(1.108,1.825)   0.006          1.345(1.047,1.728)   0.020

**Notes.**

AFPalpha fetoproteinCEAcarcinoembryonic antigenCA199carbohydrate antigen 19-9TBILtotal bilirubinALBalbuminALTalanine aminotransferaseGGTgamma glutamyltransferaseALPalkaline phosphataseHBsAghepatitis B surface antigenMVImicrovascular invasionTNMtumor-node-metastasis
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###### Independent risk factors of overall survival.

![](peerj-08-8454-g007)

  Characteristics                          Univariate           Multivariate                        
  ---------------------------------------- -------------------- -------------- -------------------- -------
  Age, year                                0.997(0.986,1.007)   0.529                               
  Sex: female vs. male                     0.980(0.757,1.269)   0.878                               
  AFP, ng/mL                               1.001(1.000,1.001)   0.011                               
  CEA, ng/mL                               1.000(0.999,1.001)   0.886                               
  CA199, ng/mL                             1.001(1.001,1.001)   \<0.001        1.001(1.000,1.001)   0.002
  TBIL, µmol/L                             1.000(0.997,1.003)   0.942                               
  ALB, g/L                                 0.953(0.928,0.979)   \<0.001        0.965(0.939,0.992)   0.012
  ALT, U/L                                 1.001(0.999,1.003)   0.381                               
  GGT, U/L                                 1.000(1.000,1.001)   0.368                               
  ALP, U/L                                 1.001(1.000,1.002)   0.014                               
  HBsAg: positive vs. negative             0.844(0.670,1.063)   0.150                               
  Tumor size, cm                           1.068(1.040,1.098)   \<0.001        1.039(1.007,1.072)   0.015
  Tumor number: multiple vs. single        1.908(1.467,2.481)   \<0.001        1.604(1.217,2.115)   0.001
  Surgical margin: \<1 cm vs. ≥1 cm        1.273(0.976,1.660)   0.075                               
  Liver cirrhosis: positive vs. negative   0.900(0.693,1.169)   0.429                               
  MVI: positive vs. negative               1.725(1.330,2.238)   \<0.001        1.345(1.026,1.763)   0.032
  TNM: III--IV vs. I--II                   1.865(1.385,2.511)   \<0.001        1.578(1.142,2.181)   0.006
  UBE2T: high vs. low                      1.609(1.259,2.057)   \<0.001        1.420(1.098,1.837)   0.008

**Notes.**

AFPalpha fetoproteinCEAcarcinoembryonic antigenCA199carbohydrate antigen 19-9TBILtotal bilirubinALBalbuminALTalanine aminotransferaseGGTgamma glutamyltransferaseALPalkaline phosphataseHBsAghepatitis B surface antigenMVImicrovascular invasionTNMtumor-node-metastasis

Discussion
==========

It is notable that the incidence rate of ICC, a rare form of liver cancer, has been rising globally over the past twenty years, which may reflect both a true increase and more accurate diagnosis of the disease ([@ref-19]; [@ref-35]). Additionally, ICC is still a poorly understood malignancy that is strongly characterized by its poor prognosis ([@ref-2]; [@ref-3]). Although scholars have revealed that some conventional medical interventions, such as adjuvant chemotherapy, antiviral therapy, and anatomical resection, might improve the prognosis of ICC patients to some extent, the 5-year OS rate is still only 40% ([@ref-14]; [@ref-24]; [@ref-26]). Thus, molecular biomarkers that are precise and targeted have the potential to become new methods for the accurate diagnosis and individualized treatment of ICC ([@ref-27]).

With the development of molecular pathology, an increasing number of biomarkers have been associated with the differential diagnosis and prognostic prediction of ICC ([@ref-23]). Regarding the differential diagnosis, [@ref-20] reported that Sex-determining region Y-box9 (Sox9) is overexpressed and associated with the carcinogenesis of ICC. Decreased Sox9 expression may be related to the early stage of ICC. Another Japanese multicenter study confirmed that Wisteria floribunda agglutinin (WFA)-sialylated mucin core polypeptide 1 (MUC1) is a useful biomarker of benign biliary tract diseases and ICC ([@ref-25]). Regarding the prediction of recurrence and prognosis, the loss of Secreted frizzled-related protein-1 (SFRP1) was shown to indicate poor disease-free survival and OS for ICC patients through its effects on the Wnt-*β*-catenin pathway ([@ref-6]). Similarly, the findings of a study analyzing 56 cases of ICC suggested that high Bim expression in tumors was correlated with better prognosis through inhibition of tumor cell proliferation and metastatic ability ([@ref-34]). However, although the molecular profile of ICC has been reviewed and emphasized, the range of application is still smaller than that of morphological subclassification ([@ref-15]; [@ref-21]), which compels us to explore additional strong biomarkers for both the differential diagnosis and prognostic prediction of ICC.

UBE2T was initially reported to be the ubiquitin-conjugating enzyme in the Fanconi anemia pathway and had a self-inactivation mechanism that could be essential for negative regulation of the Fanconi anemia pathway ([@ref-37]). Interestingly, subsequent studies showed that UBE2T downregulation inhibited the proliferation, migration, and invasion of many types of tumor cells and that its depletion significantly suppressed tumor formation and the metastasis of malignancies. For instance, Wen M et al. showed that increased UBE2T expression was associated with oncogenic properties in human prostate cancer ([@ref-32]). Wang Y et al. reported that knockdown of UBE2T inhibited the proliferation, migration, and invasion of osteosarcoma cells ([@ref-29]). [@ref-22] indicated that UBE2T was amplified in non-small cell lung adenocarcinomas and linked to recurrence after surgery. These findings may be regarded as evidence supporting the role of UBE2T as a cancer-promoting gene.

Considering the rapid tumor progression of ICC and the prominent role of UBE2T in tumor formation and development, in the present study, we performed corresponding research to investigate the effects of UBE2T on the diagnosis and prognosis of ICC. Based on the TCGA database, we confirmed that UBE2T was more highly expressed in the tumor areas than in the normal tissues of ICC patients. There was no significant difference in the prognoses of the high- and low-expression groups of ICC patients, but this may be attributed to the small number of cases and unsuitable cutoff points. Therefore, we continued to validate our hypothesis by evaluating the patients admitted to our center. First, we focused on the value of UBE2T for the differential diagnosis of ICC and other bile duct diseases. It was remarkable that the expression level of UBE2T was higher in ICC than in the IHBD, BilIN-1/2, or BilIN-3 and that UBE2T could be used as a discriminating marker between ICC and the other three tissue types. Thus, we suppose that UBE2T is a potential practical protein molecule for differential diagnoses. Second, we explored the prognostic influence of UBE2T in ICC. The X-tile software divided the ICC patients as 288 cases in the low-expression group and 113 cases in the high-expression group, and the clinical outcomes were obviously undesirable in the high-expression group. The 5-year TTR rates were 100% and 86.2% for the low- and high-expression groups, respectively, and the OS rates were 1.9% and 22.2%, respectively, for these two groups. In addition, both the univariate and multivariate Cox regression analyses revealed that UBE2T was an independent risk factor for TTR and OS. Specifically, UBE2T plays an important role in the malignant transformation and tumor development of ICC. Additionally, the results of our Cox regression analysis showed that many tumor behavior parameters, including tumor number, tumor diameter, TNM staging and liver function parameters such as ALB, are statistically significantly associated with TTR or OS. Interestingly, tumor number was a risk factor for both TTR and OS regardless of TNM staging; we hypothesize that different clonal origin patterns (intrahepatic metastasis and multicentric origin) exist in multinodular tumors and have more complex prognostic implications. Thus, we recommend that UBE2T and other risk factors be considered together in the prognostic prediction of ICC.

To our knowledge, this is the first study to demonstrate the correlation between UBE2T and ICC in a large cohort of patients. However, a prospective, multicenter cohort study is still necessary to confirm our conclusion. Furthermore, the specific molecular mechanism of UBE2T in the biological behaviors of ICC requires future investigation.

Conclusions
===========

UBE2T is a useful biomarker for the differential diagnosis of ICC. High UBE2T expression in ICC tissues is an independent indication of a poor prognosis. UBE2T is a potential drug target for molecular targeted therapy of ICC in the future.
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